Best Healthcare Companies in Center District, Israel
The 31 best Healthcare companies in Center District, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: FutuRx.
Ranked: Best Healthcare companies in Center District
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FutuRx Startup accelerator and incubator focused on Biotech | $50M | 89 mo ago | Series B | Kinneret Livnat-Savitzky CEO | 2013 | WordPressMySQLPHP+10 | — | — |
| 2 | BioLineRx Clinical stage biopharmaceutical development company | $23M | 142 mo ago | Public | Avi Molcho Co-Founder | 2003 | DrupalPHPBootstrap+17 | 206 patents Patents concentrated in health & consumer products | — |
| 3 | Mileutis Developing peptide-based antibiotics for human and animal health | $20M | 72 mo ago | Series A | David Javier Iscovich CEO | 2005 | — | 78 patents Improving milk quality and treating skin/mammary disorders using casein hydrolysate formulations. | — |
| 4 | Kadimastem Stem Cell for the treatment of diabetes mellitus and amyotrophic lateral sclerosis (ALS) | $18M | 60 mo ago | Public | — | 2009 | WixSentryBootstrap+12 | 46 patents Patents concentrated in chemistry & materials | — |
| 5 | XTL Biopharmaceuticals Protein therapeutics for inflammatory diseases such as systemic lupus erythematosus and multiple myeloma. | $11M | 26 mo ago | Public | — | 1993 | WordPressMySQLPHP+12 | 21 patents Peptide therapeutics for lupus and antiviral small‑molecule/antibody formulations | — |
| 6 | Optimata Develops technologies for predicting improved patient therapy and manufactures medical devices for oncology | $2M | 106 mo ago | Series A | Zvia Agur Founder & CSO | 2000 | — | 35 patents Patents concentrated in computing, sensing & instrumentation | — |
| 7 | Medibrane Manufacturer of medical device components using advanced polymer coating technologies | $383K | 89 mo ago | Seed | Amir Kraitzer Founder and CTO | 2014 | WordPress Block EditorElementorWordPress+30 | 18 patents Bonded stent assembly manufacturing and 3D‑printed catheter shaft production for cardiovascular devices. | — |
| 8 | Earways Medical Manufacturer of ear care products | $111K | 86 mo ago | Funding Raised | Amir Kraitzer Founder and CTO | 2014 | — | — | — |
Top 9 Healthcare companies in Center District
#1
Public · Ra anana, Center District · founded 1993 · 4 employees$10.6Mraised▾
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development: hCDR1 peptide for the treatment of Systemic Lupus Erythematosus (SLE) (Phase 2); Recombinant Erythropoietin (rHuEPO) for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival (Phase 1).
#2
Public · Ness Ziona, Center District · founded 2009 · 31 employees$18.2Mraised▾
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin-secreting as a range of neural cells (Oligodendrocytes, Astrocytes). Based on its differentiation technologies, the company is advancing two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells (for the diabetes program) and astrocytes (for the ALS program) with the goal of implanting them into patients, and affecting diseases progression. Also collaborating for optimizing drug development through pluripotent stem cell-derived cells.
- Oct 2021Post IPO$5M
- Oct 2018Post IPO$5.2M
- Mar 2018Grant (prize money)$319.4K
- Dec 2016Post IPO$7M
#3
Series B · Ness Ziona, Center District · founded 2013 · 18 employees$49.7Mraised▾
FutuRx is a startup accelerator and incubator. The incubation period spans over 3 years and accepts startups working in the Biotech sector.
- May 2019Series B$19.7M
- May 2017Series A$30M
#4
Series A · Gan Yavne, Center District · founded 2005 · 38 employees$20Mraised▾
Mileutis is a biopharmaceutical company focused on the discovery and development of peptide-based antimicrobial therapies for animal and human health. Its human drug pipeline has 3 candidates namely MLT-4, MLT-1002 and MLT-1003 in the development stage for breast inflammation & programmable cell death. It also has 5 animal drug candidates with four of them available for licensing.
#5
Public · Modi in Maccabim Re ut, Center District · founded 2003 · 49 employees$23Mraised▾
BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. It in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx's pipeline currently consists of six clinical stage therapeutic candidates which could be used in case of acute myeloid leukemia (AML), celiac disease, non-surgical removal of skin lesions, inflammatory bowel disease, interferon-free treatment for Hepatitis C, a medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients. It also has a multi-year strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates.
#6
Series A · Bnei Atarot, Center District · founded 2000 · 11 employees$1.5Mraised▾
Operator of a bio-pharmaceutical company aiming at accelerating the long and costly process of drug development. The company provides computer technologies for predicting improved patient therapy high level multi-scale modeling that integrates rational analysis of treatment mechanism of action and efficacy, together with information from large data bases, enabling patients receive the best drug therapy thus facilitating improved treatment decisions in malignant diseases.
#7
Seed · Rosh Haayin, Center District · founded 2014 · 20 employees$383.5Kraised▾
Manufacturer of medical device components using advanced polymer coating technologies. It provides prototype design and manufacturing services, specializing in polymer treatment, sutureless laminations, and ePTFE sintering. The company offers a selection of materials including silicone, polyurethane, ePTFE, and Dacron, tailored for medical stent manufacturing and other applications within the neurovascular, structural heart, and endovascular fields. Its capabilities encompass microlayer polymer deposition, dip and spray coating, and post-processing techniques to create high-quality solutions for medical device development.
- Jun 2019Seed—
- Jun 2019Conventional Debt—
- Jan 2019Grant (prize money)$383.5K
- Nov 2018Seed—
#8
Funding Raised · Rosh Haayin, Center District · founded 2014 · 4 employees$111.1Kraised▾
Developer of an ear-care medical device designed to remove earwax. The company's device is based on a clinically proven, innovative, patented technology with a flexible coated helical, open profile tip for easy navigation in the ear canal and is used for cerumen extraction, management, and impaction of earwax, it provides easy-to-use ear care products designed for clinicians and use at home and benefits from a team of experts in bioengineering, medical devices, ear surgery, hearing loss, and rehabilitation, enabling physicians to treat and prevent the temporary loss of hearing due to earwax clogging.
- Aug 2019Grant (prize money)$55.1K
- May 2019Grant (prize money)$56K
#9
Public · Ness Ziona, Center District · founded 2005 · 56 employees—raised▾
Operator of a clinical-stage company focused on developing bio-better, long-acting versions of therapeutic proteins and peptide drugs. The company's carboxyl-terminal peptide (CTP) and reversible PEGylation technologies can be attached to an array of existing therapeutic proteins for stabilizing the therapeutic peptides and small molecules in the bloodstream and extending their lifespan without additional toxicity or loss of desired biological activity, enabling doctors to effectively treat children and adults with growth hormone deficiency.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.